Latest filing published 21 May 2026 for 지투지바이오.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -37.8%Entry ₩71,900 · Close 07 Oct 2026 ₩44,700
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
최희경: trading record in brief
최희경 is a declared insider of 지투지바이오 (chief executive), with filings sourced from DART (FSS). In total, 3 filings cover trades dated from 6 November 2025 to 21 May 2026.
Purchases make up the whole of the open-market record (3 purchases, €32k). The amount is not disclosed for 2 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2026, the count stands at 2 purchases and no sales.
The latest filing, published on 21 May 2026, reports an open-market purchase in 지투지바이오. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Companies and markets linked to 최희경
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 3,000 sharesShareKRXDART:20260521000756Canonical exit: 13 Aug 2026 (T+90)
- 718 shares@ ₩77,100.000.0075% mcap100.0% of flowShareKRXDART:20260327000306Canonical exit: 23 Jun 2026 (T+90)
- 40,148 sharesShareKRXDART:20251106000318Canonical exit: 4 Feb 2026 (T+90)
3 of 3 declarations